CN101966272A - Chinese medicinal composition for treating proliferative diseases - Google Patents
Chinese medicinal composition for treating proliferative diseases Download PDFInfo
- Publication number
- CN101966272A CN101966272A CN 201010504053 CN201010504053A CN101966272A CN 101966272 A CN101966272 A CN 101966272A CN 201010504053 CN201010504053 CN 201010504053 CN 201010504053 A CN201010504053 A CN 201010504053A CN 101966272 A CN101966272 A CN 101966272A
- Authority
- CN
- China
- Prior art keywords
- medicine
- application
- treatment
- tumor
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to Chinese medicinal zengshengpin for treatment, which comprises the following components in part by weight: 18 to 24 parts of vietnamese sophora root, 17 to 21 parts of bistort rhizome, 17 to 23 parts of dahurian patrinia herb, 8 to 12 parts of densefruit pittany root-bark, 18 to 25 parts of common selfheal fruit-spike and 3 to 6 parts of air potato.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, particularly the Chinese medicine of treatment mammary gland tumor.
Background technology:
90109821.3 of Chinese patents are called the preparation technology that " preparation technology of canceration shutoff agent " zengshengping tablet " " described a kind of zengshengping tablet, become extractum through the extraction with aqueous solution effective ingredient, make different dosage form then and form.Through experiment of rat and dog and 2531 routine epithelium of esophagus severe hypertrophy patients' observation, the result shows that " zengshengping tablet " is a kind of tumor prevention agent of novel blocking-up carcinogenesis.
Consisting of of each component of hypertrophy plain film that Chinese patent 90109821.3 is described: Rhizoma Dioscoreae Bulbiferae 3-6, Spica Prunellae 18-25, Rhizoma Bistortae 17-21, Herba Patriniae 17-23, Radix Sophorae Tonkinensis 18-24, Cortex Dictamni 8-12.
Wherein used this composition of Herba Patriniae, Herba Patriniae is the herb of Valerianaceae plant patrima villosa Patrinia vi1losa Juss..[another name] Patrinia scabiosaefolia Fisch, imperial bud Herba Patriniae, Herba Patriniae, bent dish [source] this product are the plant Hemerocallis citrina Baroni dragon bud Patrinia scabiosaefolia Fisch.ex Link. of Herba Patriniae section, patrima villosa (bitter vegetarian) P.villosa (Thunb.) Juss. is with root stock and root, all herbal medicine.Root is excavated season in spring and autumn, removes stem and leaf and cleans, and dries.Autumn in herb summer taps, and cleans and dries.[method for making] cleaned, and dries, and chopping is used.
[meridian distribution of property and flavor] is hot, bitter, cold.Go into stomach, large intestine, Liver Channel.[function cures mainly] heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, blood circulation promoting competent silt.Be used for acute appendicitis, lung abscess and sore and toxic, the breast abdomen pain due to the excess-heat stasis of blood stagnates, the stagnant stomachache of the stasis of blood in puerperal waits disease.
Sonchus brachyotus DC. is the Compositae Herba Sonchi Oleracei, belongs to the dry young tender herb of herbaceos perennial Herba Sonchi Arvensis Sonchus arvensis L..Pharmacopoeia of the People's Republic of China Herba Sonchi Arvensis just by name.[nature and flavor and effect] hardship, cold.The function that heat-clearing and toxic substances removing, detumescence and apocenosis, blood stasis dispelling are arranged.[clinical practice] is used for appendicitis, enteritis, dysentery, skin ulcer furuncle carbuncle, hemorrhoid, postnatal blood stasis stomachache.[consumption] fries in shallow oil soup 9～15g for oral administration.The bright product of external are an amount of, mash deposited affected part, or fry in shallow oil the soup fumigation and wash method.[former plant] rhizome is elongated cylindrical, and is gradually thin downwards, long 3～10cm, diameter 2～5mm; The surface light yellowish brown has vertical wrinkle, and the leaf scar of near-ring shape projection is arranged at top, and tiny adventitious root is arranged at the bottom, or the root trace of projection.Long 1～the 6cm of children's stem, basal leaf is crispaturaed or is broken, is oval shape lanceolar or wide lanceolar after complete person flattens, long 4～16cm, wide 0.5～3.5cm, tip justify blunt or short point more, stimuli is arranged, what the leaf margin tool was sparse incises or irregular pinnation, or does not divide, and there is little pointed tooth at the edge, every cm is interior more than 5, the upper surface celadon, the following table complexion is more shallow, the gradually narrow one-tenth handle of base portion; The spire surface is close by young pilose antler; The stem leaf alternate, similar to basal leaf, but base portion ear shape is embraced stem.Matter is crisp.Feeble QI, it is little salty to distinguish the flavor of.Mammary gland tumor comprises: cyclomastopathy, and breast tumor, galactocele, wherein breast tumor comprises mammary gland benign tumor and breast carcinoma.
Cyclomastopathy is the modal cystic hyperplasia of breast of women, and its sickness rate accounts for the first place of mastopathy.Should be the trend that rises year by year by the disease sickness rate in the last few years, the age also more and more becomes younger.There is 70%～80% women that in various degree cyclomastopathy is all arranged according to investigations approximately, is more common in the 25--45 women in year.Mastalgia and lump are the performance of primary disease main clinical.
Think at present that cyclomastopathy is that morbidity is extensive because the variation of human body inner estrogen and progestogen causes, symptom is obvious before and after general menstrual period more, and through treatment, postmenopausal symptom does not disappear majority substantially.The clinical treatment medicine mostly is the hormonal regulation medicine.The sickness rate of the cyclomastopathy that is not true to type is low, but it is bigger to change the probability of breast carcinoma into.
The major lesions of cystic cyclomastopathy is: 1. cystic disease; 2. papillomatosis; 3. latex dust epithelial proliferation; 4. adenopathy; 5. metaplasia apocrine.Wherein with 1. 2. 3. in close relations with breast carcinoma.Cause: the other pathological changes of breast carcinoma cancer is almost all with cyclomastopathy, much more comparatively the other atypical hyperplasia of cancer to see around ILC, carcinoma simplex and the infiltrating cancer, and diameter of tumor is littler based on the cystic cyclomastopathy canceration, the other atypical hyperplasia of its cancer is the more seen, and hyperplasia degree is more serious; Diameter of tumor is bigger, and atypical hyperplasia is more rare, and hyperplasia degree is light more, even can not find atypical hyperplasia.
Mammary gland is caused a series of Histological changes under the carcinogenic factor effect, and it all is on breast epithelium popularity hypertrophy pathological changes basis and take place that breast carcinoma and many originality thereof are sent out the kitchen range pathological changes, shows that breast carcinoma is not isolated local patholoic change.Atypical hyperplasia is the other pathological changes of important cancer, its existence and degree and histological type, the tumor size is closely related, be precancerous lesion in morphologic reflection, can develop into cancer in situ under certain condition.
Breast carcinoma is one of modal malignant tumor of women, usually occurs in breast glandular epithelium tissue.According to statistics, sickness rate accounts for the 7-10% of the various malignant tumor of whole body, is only second to uterus carcinoma the women.Its morbidity is normal relevant with heredity, and between 40--60 year, menopause, women's sickness rate of front and back was higher.
The Therapeutic Method of breast carcinoma has multiple, and doctor trained in Western medicine is first-selected with the excision, and combination with radiotherapeutic, change furuncle, endocrine therapy and immunotherapy etc., but put, chemotherapy produces effect to local tumor, but toxicity is very big, and patient's whole body is had very macrolesion.And effect and the advantage of Chinese medicine in the breast carcinoma Comprehensive Treatment is subjected to the attention of domestic and international clinical tumor circle day by day.Effectively Chinese medicine and operation, chemicotherapy, endocrine therapy, immunotherapy are combined, improving postoperative patient muscle power, transfer body resistance against diseases, alleviate the chemicotherapy toxicity, improving the quality of living, control tumor recurrence and shift, important function and unique advantage are arranged aspect prolonging life cycle.
Chinese patent as:
02146486.3 Chinese medicine for the treatment of cyclomastopathy
02153458.6 treat pharmaceutical composition of cyclomastopathy and preparation method thereof for one kind
02138009.0 Chinese medicine composition of treatment cyclomastopathy and preparation method thereof
95111935.4 medicine for the treatment of cyclomastopathy
96115288.5 drug preparation Sanru oral liquor that is used for the treatment of cyclomastopathy
93107661.7 be used for the treatment of the medicine and the compound method thereof of cyclomastopathy
94108193.1 resisting hyperplasia of mammary glands Chinese patent medicine
98106592.9 medicine for treating hyperplasia of mammary glands and stopping pain
200,610,028,556 1 kinds of medicines for the treatment of cyclomastopathy and breast tumor and preparation method thereof
The Chinese medicinal formulae of 97,105,153 1 kinds of treatment mastadenoma (cancer)
Above patent has been described the compound Chinese medicinal preparation of some treatment cyclomastopathy and breast tumor, and these medicines belong to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is on stream because uncertain therapeutic efficacy is cut interrupts developing.
The present invention is according to experimental research achievements, and unexpected the discovery replaces Herba Patriniae to make drug Zengshengping to treating mammary gland tumor can obtain better effect with Sonchus brachyotus DC., below is content of the present invention.
Summary of the invention:
The invention provides a kind of Chinese medicine preparation and the application in the medicine of preparation treatment mammary gland tumor thereof,
Chinese medicine preparation of the present invention, it is composed as follows to fill a prescription:
Radix Sophorae Tonkinensis 18-24 part, Rhizoma Bistortae 17-21 part, Sonchus brachyotus DC. 17-23 part, Cortex Dictamni 8-12 part, Spica Prunellae 18-25 valency, Rhizoma Dioscoreae Bulbiferae 3-6 part.
In more than forming, weight is calculated with crude drug, by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or is unit with the ton, and small-scale production can be a unit with gram or milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Tablet most preferably.
Chinese medicine preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as adhesive, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to preparation in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The most preferred preparation method of Chinese medicine preparation of the present invention is as follows:
Prescription:
Radix Sophorae Tonkinensis 420g, Rhizoma Bistortae 420g, Sonchus brachyotus DC. 420g, Cortex Dictamni 210g, Spica Prunellae 420g,
Rhizoma Dioscoreae Bulbiferae 100g
Preparation:
Get Cortex Dictamni 210g, it is standby to be ground into fine powder.Get each 420g of Rhizoma Dioscoreae Bulbiferae 100g, Radix Sophorae Tonkinensis, Sonchus brachyotus DC., Rhizoma Bistortae and Spica Prunellae again, put in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, be evaporated to relative density and survey 1.30 to 1.35 extractum for 50 ℃.With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add excipient at last, be pressed into the 0.3g sheet and get final product.
Medicine of the present invention is used for the treatment of mammary gland tumor, and described mammary gland tumor comprises: cyclomastopathy, and breast tumor, galactocele, wherein, cyclomastopathy comprises common cyclomastopathy and the cyclomastopathy that is not true to type, breast tumor comprises mammary gland benign tumor and breast carcinoma.
Therefore, the present invention includes the application of medicine of the present invention in the medicine of preparation treatment mammary gland tumor.
The application of medicine of the present invention in preparing the medicine for the treatment of the cyclomastopathy that is not true to type.
The application of medicine of the present invention in the medicine of the common cyclomastopathy of preparation treatment.
The application of medicine of the present invention in the medicine of preparation treatment mammary gland benign tumor.
The application of medicine of the present invention in the medicine of preparation treatment adenocarcinoma.
The application result of relevant medicine of the present invention is as follows:
With the medicine of the present invention of most preferred method of the present invention preparation, clinical cooperation center is to the patient of 121 routine cystic hyperplasia of breast in the whole nation, oral medicine of the present invention, and every day 2 times, each 8,60 days is a course of treatment.The result: in 121 examples, 72 examples of fully recovering account for 59.5%, and 37 examples that take a turn for the better account for 30.6%, and invalid 12 examples account for 9.9%, total effective rate 90.1%.
Clinical efficacy, medicine group 32 examples of the present invention with chemotherapeutic treatment breast carcinoma before the medicine cooperation art of the present invention of most preferred method preparation of the present invention. observation group's 25 examples, two groups of chemotherapy adopt: cyclophosphamide ((CTX) 400～600mg/m
2, intravenous injection, fluorouracil (5-Fu) 400mg/m
2, intravenous drip, all medication in the 1st day, 21 days was 1 cycle, 2～3 cycles of chemotherapy before the art, the operation after 14 days of having a rest.Medicine group of the present invention gave in chemotherapy in preceding 5 days, and every day 3 times, 7 days was 1 course of treatment.The result: short term effect compares, and Chinese drug-treated group effective percentage (83.5%) is apparently higher than matched group (70.8%) (P＜0.05).
Below data further specify beneficial effect of the present invention by experiment:
One, medicine of the present invention is to the therapeutical effect experiment of rabbit cyclomastopathy
(1) method:
1, preparation hyperplasia of mammary gland model: 38 of rabbits at first are divided into two groups, and wherein normal group is 10,28 of model group.Normal group rabbit intramuscular injection every day normal saline 0.5ml/kg, model group intramuscular injection estradiol (E
2) injection 1mg/kg, after continuous 30 days, blood sampling detects sex hormone level in the gross examination of skeletal muscle breast shape, ventricle, comprises estradiol (E
2), progesterone (P), short breast soak ripe hormone (FSH), interstitialcellstimulating hormone (ICSH) (PrL).
2, experiment grouping: except that normal group, 24 rabbit of model group are further divided into matched group and medicine group of the present invention, 12 every group.Medicine 0.5g/kg of the present invention group is mixed medicated powder and is fed fosterly in a spot of feedstuff, after waiting to have eaten, gives normal feedstuff again, every day secondary; Normal group and matched group are given conventional feed and are fed, and continuous use 30d observes the variation of These parameters.
(2), experimental result:
1, E
2The rabbit hyperplasia of mammary gland model of duplicating:
The hyperplasia of mammary gland model general form is learned discrimination standard:
1) red, swollen, big three does not all have the person to be +++.
2) swollen, the two does not all have the person to be greatly ++.
3) become merely big person into+.
4) the no change person be-.
Model group is at E
2After using 30d, visible mammary gland increases (the results are shown in Table 1).
Table 1 normal group and model group mammary gland increase degree are relatively
2. medicine of the present invention is to the therapeutic effect of cyclomastopathy
(1) general form is learned the influence that changes:
Result's (table 2) is through the rank test statistics, and medicine of the present invention and matched group compare, and the visible medicine of the present invention of significant difference (P＜0.01) can suppress the rabbit mammary gland enlargement that estrogen causes.
Table 2 medicine of the present invention increases the influence of degree to mammary gland
(2) to the influence of sex hormone level:
Result's (table 3) as seen, E in the blood
2With the P level, be starkly lower than matched group (P＜0.05) in medication therapy groups of the present invention, medicine of the present invention can reduce E
2With the level of P, thereby to resisting hyperplasia of mammary glands.
Table 3 medicine of the present invention to the influence of sex hormone level in the cyclomastopathy rabbit body (X ± S, n=6)
Two, medicine of the present invention to rat breast cancer before the inhibitory action of hypertrophy (atypical hyperplasia of mammary)
Experiment purpose: utilize DMBA (DMBA) to induce atypical hyperplasia of mammary, inquire into medicine of the present invention to rat breast cancer before outgrowth inhibitory action.
Test method: not copulation female sd inbred rats of 60 42-50d is divided into 3 groups at random; 20 of blank groups give conventional the raising; 20 of sick modules adopt DMBA (DMBA) 80mg/kg oil solution to irritate stomach; 20 of medicine groups of the present invention adopt DMBA (DMBA) 80mg/kg oil solution to irritate the drug-admixed food of the present invention that gives 0.5g/kg on the basis of stomach and feed.Put to death during the 20th weekend and respectively organize rat, get whole mammary gland and carry out histological observation.
The result:
1, hypertrophy statistics
※Compare P＜0.05 with the blank group;
※ ※Compare P＜0.05 with sick module
2, sprout, real group statistics
※Compare P＜0.05 with the blank group;
※ ※Compare P＜0.05 with sick module
3, microvessel density statistics
Medicine group microvessel density of the present invention is starkly lower than the disease module, P＜0.05.
4, papilloma, division are added up mutually
※Compare P＜0.05 with the blank group;
※ ※Compare P＜0.05 with sick module.
Conclusion: medicine of the present invention to the inductive rat breast cancer of DMBA before hypertrophy (atypical hyperplasia of mammary) inhibited.
Three, medicine of the present invention is tested the therapeutical effect of breast carcinoma:
1, observe the inhibitory action of medicine of the present invention to transplantability mouse breast cancer (EMT_6) growth,
Method is carried out the filling stomach in 3 weeks by a definite date to tumor-bearing mice, and intraperitoneal injection of cyclophosphamide (CTX) is judged the inhibitory action of medicine of the present invention to mice-transplanted tumor by tumour inhibiting rate.
Result's medicine of the present invention is respectively 28.29%, 26.28% to tumor-bearing mice tumor size, the heavy suppression ratio of tumor, and the CTX group is 46.5%, 47.62%, and medicine of the present invention+CTX group is 66.77%, 68.86%.
Conclusion (1) medicine of the present invention has tumor-inhibiting action preferably.(2) medicine of the present invention presses down tumor to CTX potentiation.
2, observe medicine of the present invention to mice transplanted tumor U14, and the antitumor activity of Lewis ' LC
Inoculated tumour is subcutaneous in the right axil of mice under the conventional sterile working of method, begins administration behind the 24h, and 3 dosage groups of medicine of the present invention are 2.5,5.0 and 10.0g/kg, oral administration 10～14 days, blank group clothes animal housing dedicated water, positive controls give CTX (20mg/kg * 10-14d, ip).24h puts to death animal after the drug withdrawal, strips the tumor knot and weighs, and calculates tumour inhibiting rate.
CTX is respectively 59.32% and 57.91% to the tumour inhibiting rate of U14 and EMT6 as a result, and medicine group of the present invention is 51.28% and 52.54%.Conclusion and matched group compare, difference highly significant (P＜0.01).
Four, clinical observation
The patient of 121 routine cystic hyperplasia of breast, oral medicine of the present invention, every day 2 times, each 8,60 days is a course of treatment.The result: in 121 examples, 72 examples of fully recovering account for 59.5%, and 37 examples that take a turn for the better account for 30.6%, and invalid 12 examples account for 9.9%, total effective rate 90.1%.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Get Cortex Dictamni 210g, it is standby to be ground into fine powder.Get each 420g of Rhizoma Dioscoreae Bulbiferae 100g, Radix Sophorae Tonkinensis, Sonchus brachyotus DC., Rhizoma Bistortae and Spica Prunellae again, put in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, be evaporated to the extractum of relative density 1.30 to 1.35 (50 ℃ of heat are surveyed).With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add excipient at last, be pressed into the 0.3g sheet and get final product.
Embodiment 2
Get Cortex Dictamni 230g, it is standby to be ground into fine powder.Get Rhizoma Dioscoreae Bulbiferae 120g, Radix Sophorae Tonkinensis 480g, Sonchus brachyotus DC. 420g, Rhizoma Bistortae and each 420g of Spica Prunellae again, put in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, be evaporated to the extractum of relative density 1.20 to 1.45 (50 ℃ of heat are surveyed).With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add an amount of excipient and make electuary at last.
Embodiment 3
Get Cortex Dictamni 150g, it is standby to be ground into fine powder.Get Rhizoma Dioscoreae Bulbiferae 60g, Radix Sophorae Tonkinensis 360g, Sonchus brachyotus DC. 340g, Rhizoma Bistortae 340g and Spica Prunellae 360g again, put in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, be evaporated to the extractum of relative density 1.30 to 1.35 (50 ℃ of heat are surveyed).With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add an amount of excipient at last, be pressed into coated tablet and get final product.
Claims (10)
1. medicine for the treatment of mammary gland tumor is characterized in that being prepared from by following raw material of Chinese medicine medicine:
Radix Sophorae Tonkinensis 18-24 part, Rhizoma Bistortae 17-21 part, Sonchus brachyotus DC. 17-23 part, Cortex Dictamni 8-12 part, Spica Prunellae 18-25 part, Rhizoma Dioscoreae Bulbiferae 3-6 part.
2. according to the medicine of claim 1, it is characterized in that being prepared from by following raw material of Chinese medicine medicine:
Radix Sophorae Tonkinensis 420g, Rhizoma Bistortae 420g, Sonchus brachyotus DC. 420g, Cortex Dictamni 210g, Spica Prunellae 420g, Rhizoma Dioscoreae Bulbiferae 100g
3. the preparation method of the medicine of claim 1 is characterized in that step is as follows:
Get Cortex Dictamni 210g, it is standby to be ground into fine powder.Get each 420g of Rhizoma Dioscoreae Bulbiferae 100g, Radix Sophorae Tonkinensis, Sonchus brachyotus DC., Rhizoma Bistortae and Spica Prunellae again, put in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, be evaporated to relative density and survey 1.30 to 1.35 extractum for 50 ℃.With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add excipient at last, be pressed into the 0.3g sheet and get final product.
4. the application of the medicine of claim 1 in the medicine of preparation treatment mammary gland tumor.
5. the application of claim 4, wherein said medicine, its using method is as follows: determines usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
6. the application of claim 4, wherein said application comprises the auxiliary treatment of tumor, and unites use with other antitumor drug.
7. the application of claim 4, the wherein said application that is applied as in the medicine for the treatment of the cyclomastopathy that is not true to type.
8. the application of claim 4, the wherein said application that is applied as in the medicine for the treatment of common cyclomastopathy.
9. the application of claim 4, the wherein said application that is applied as in the medicine for the treatment of mammary gland benign tumor.
10. the application of claim 4, the wherein said application that is applied as in the medicine for the treatment of adenocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010504053 CN101966272A (en) | 2009-10-21 | 2010-10-12 | Chinese medicinal composition for treating proliferative diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910206710A CN101670034A (en) | 2009-10-21 | 2009-10-21 | Application of traditional Chinese drug Zengshengping to treating mammary gland tumor |
| CN200910206710.9 | 2009-10-21 | ||
| CN 201010504053 CN101966272A (en) | 2009-10-21 | 2010-10-12 | Chinese medicinal composition for treating proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101966272A true CN101966272A (en) | 2011-02-09 |
Family
ID=42017590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910206710A Pending CN101670034A (en) | 2009-10-21 | 2009-10-21 | Application of traditional Chinese drug Zengshengping to treating mammary gland tumor |
| CN 201010504053 Pending CN101966272A (en) | 2009-10-21 | 2010-10-12 | Chinese medicinal composition for treating proliferative diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910206710A Pending CN101670034A (en) | 2009-10-21 | 2009-10-21 | Application of traditional Chinese drug Zengshengping to treating mammary gland tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101670034A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188588A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Hyperplasia relieving granule composition and preparation method thereof |
| CN102188589A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping oral liquid composition and preparation method thereof |
| CN102188587A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping effervescent tablet composition and preparation method thereof |
| CN102188590A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping dispersing tablet composition and preparation method thereof |
| CN110638919A (en) * | 2018-06-26 | 2020-01-03 | 中国医学科学院药物研究所 | Improved low-toxicity zengshengping composition and preparation method and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125646B (en) * | 2011-03-01 | 2013-05-08 | 天津康晨瑞信医药集团有限公司 | Application of Chinese medicinal composition to treatment of stomach chronic inflammation with intestinal metaplasia and intraepithelial neoplasia |
| CN102114164A (en) * | 2011-03-01 | 2011-07-06 | 天津康晨瑞信医药集团有限公司 | Application of traditional Chinese medicine preparation in treating oral leukoplakia and preventing diseases caused by oral leukoplakia canceration |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062656A (en) * | 1990-12-20 | 1992-07-15 | 中国医学科学院肿瘤研究所 | The preparation technology of canceration shutoff agent " zengshengping tablet " |
-
2009
- 2009-10-21 CN CN200910206710A patent/CN101670034A/en active Pending
-
2010
- 2010-10-12 CN CN 201010504053 patent/CN101966272A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062656A (en) * | 1990-12-20 | 1992-07-15 | 中国医学科学院肿瘤研究所 | The preparation technology of canceration shutoff agent " zengshengping tablet " |
Non-Patent Citations (5)
| Title |
|---|
| 《中药学》 19930831 李钟文主编 败酱草 中国中医药出版社出版 第53页 1-3 , * |
| 《中西医结合防治肿瘤》 19951031 孙燕等主编 增生平片抗癌防癌作用的研究 北京医科大学中国协和医科大学联合出版社 第238页 1-10 , 第1版 1 * |
| 《常见病中西医结合诊疗常规》 20031130 罗云坚等主编 增生平片 广东科技出版社 第389页 7-9 , 第1版 1 * |
| 《彩色图解中药饮片鉴别手册》 20020131 沈连生主编 败酱草 北败酱 华夏出版社出版 第36页 1-3 , * |
| 《肿瘤病人康复手册》 20030131 张文彭等主编 增生平片 人民卫生出版社 349页 1-6，10 , 第1版 1 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188588A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Hyperplasia relieving granule composition and preparation method thereof |
| CN102188589A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping oral liquid composition and preparation method thereof |
| CN102188587A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping effervescent tablet composition and preparation method thereof |
| CN102188590A (en) * | 2011-04-27 | 2011-09-21 | 天津康晨瑞信医药集团有限公司 | Zengshengping dispersing tablet composition and preparation method thereof |
| CN102188589B (en) * | 2011-04-27 | 2016-07-13 | 天津康晨瑞信医药集团有限公司 | A kind of zengshengping tablet oral liquid composition and method of making the same |
| CN102188590B (en) * | 2011-04-27 | 2016-08-03 | 天津康晨瑞信医药集团有限公司 | A kind of Zengshengping dispersing tablet composition and preparation method thereof |
| CN102188588B (en) * | 2011-04-27 | 2016-08-03 | 天津康晨瑞信医药集团有限公司 | A kind of hyperplasia relieving granule composition and preparation method thereof |
| CN102188587B (en) * | 2011-04-27 | 2016-08-03 | 天津康晨瑞信医药集团有限公司 | A kind of Zengshengping effervescent tablet composition and preparation method thereof |
| CN110638919A (en) * | 2018-06-26 | 2020-01-03 | 中国医学科学院药物研究所 | Improved low-toxicity zengshengping composition and preparation method and application thereof |
| CN110638919B (en) * | 2018-06-26 | 2022-06-21 | 中国医学科学院药物研究所 | Improved low-toxicity zengshengping composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101670034A (en) | 2010-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101966272A (en) | Chinese medicinal composition for treating proliferative diseases | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN115040602A (en) | Pharmaceutical composition for improving hyperplasia of mammary glands and preparation method thereof | |
| KR20140144516A (en) | A composition comprising the complex extract of Rehmannia glutinosa and Pueraria lobata for preventing or treating female menopausal disorder | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN101744986B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101744993B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN1931271A (en) | Evodia extract and its prepn process, medicine composition and use | |
| CN106390035A (en) | Traditional Chinese medicine preparation for treating mammary gland hyperplasia | |
| CN107198727A (en) | A kind of pharmaceutical composition of beautifying face and moistering lotion promoting blood circulation for regulating menstruation and preparation method thereof | |
| CN101744996B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN113332374A (en) | Application of traditional Chinese medicine composition in preparation of medicine for inhibiting endometrial hyperplasia | |
| CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN104771553A (en) | Invigorating spleen and kidney preparation for treatment of gastric cancer and preparation method thereof | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
| CN101744999B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| KR102408605B1 (en) | Composition for preventing or treating female menopausal disorder and bone diseases comprising complex extract of Sopora japonica L., Pueraria lobata (Wild.) Ohwi and germinated Glycine max (L.) Merr embryo | |
| CN101744987B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN105943579A (en) | Pharmaceutical composition for treating gastric cancer and preparation method of pharmaceutical composition | |
| CN101744990B (en) | Method for individually extracting ginseng, radix ophiopogonis and schisandra chinensis and preparation thereof | |
| CN101744994B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN106177391A (en) | A kind of pharmaceutical composition treating cancer and preparation method thereof | |
| CN106538787B (en) | A kind of Chinese medicine composition and preparation method thereof for preventing and treating female dimacteric syndrome | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
| CN103784504B (en) | A kind of Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110209 |